R
Ruth N. Moro
Researcher at Centers for Disease Control and Prevention
Publications - 17
Citations - 902
Ruth N. Moro is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Rifapentine & Latent tuberculosis. The author has an hindex of 11, co-authored 15 publications receiving 710 citations.
Papers
More filters
Journal ArticleDOI
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
M. Elsa Villarino,Nigel A. Scott,Stephen E. Weis,Marc H Weiner,Marcus Barreto Conde,Brenda E. Jones,Sharon Nachman,Ricardo R. Oliveira,Ruth N. Moro,Nong Shang,Stefan V. Goldberg,Timothy R. Sterling +11 more
TL;DR: Treatment with the combination of rifapentine and isoniaZid was as effective as isoniazid-only treatment for the prevention of tuberculosis in children aged 2 to 17 years and was safe.
Posted ContentDOI
First 12 patients with coronavirus disease 2019 (COVID-19) in the United States
Stephanie A Kujawski,Karen K. Wong,Jennifer P Collins,Lauren Epstein,Marie E Killerby,Claire M Midgley,Glen R. Abedi,N Seema Ahmed,Olivia Almendares,Francisco N Alvarez,Kayla N. Anderson,Sharon Balter,Vaughn Barry,Karri Bartlett,Karlyn D. Beer,Michael Ben-Aderet,Isaac Benowitz,Holly M. Biggs,Alison M. Binder,Stephanie R. Black,Brandon Bonin,Catherine M. Brown,Hollianne Bruce,Jonathan Bryant-Genevier,Alicia P. Budd,Diane Buell,Rachel Bystritsky,Jordan Cates,E. Matt Charles,Kevin Chatham-Stephens,Nora Chea,Howard Chiou,Demian Christiansen,Victoria T Chu,Sara Cody,Max Cohen,Erin E. Conners,Aaron T. Curns,Vishal Dasari,Patrick Dawson,Traci DeSalvo,George A. Diaz,Matthew Donahue,Suzanne Donovan,Lindsey M. Duca,Keith Erickson,Mathew D. Esona,Suzanne Evans,Jeremy A. Falk,Leora R. Feldstein,Martin Fenstersheib,Marc Fischer,Rebecca Fisher,Chelsea Foo,Marielle J Fricchione,Oren Friedman,Alicia M. Fry,Romeo R. Galang,Melissa M. Garcia,Susa I. Gerber,Graham Gerrard,Isaac Ghinai,Prabhu Gounder,Jonathan Grein,Cheri Grigg,Jeffrey D. Gunzenhauser,Gary I. Gutkin,Meredith Haddix,Aron J. Hall,George S Han,Jennifer L Harcourt,Kathleen Harriman,Thomas Haupt,Amber K. Haynes,Michelle Holshue,Cora Hoover,Jennifer C. Hunter,Max W. Jacobs,Claire Jarashow,Michael A. Jhung,Kiran Joshi,Talar Kamali,Shifaq Kamili,Lindsay Kim,Moon Kim,Jan King,Hannah L Kirking,Amanda Kita-Yarbro,Rachel Klos,Miwako Kobayashi,Anna Kocharian,Kenneth Komatsu,Ram Koppaka,Jennifer E Layden,Yan Li,Scott Lindquist,Stephen Lindstrom,Ruth Link-Gelles,Joana Y Lively,Michelle Livingston,Kelly Lo,Jennifer Lo,Xiaoyan Lu,Brian Lynch,Lawrence C. Madoff,Lakshmi Malapati,Gregory Marks,Mariel Marlow,Glenn E. Mathisen,Nancy McClung,Olivia L McGovern,Tristan D. McPherson,Mitali Mehta,Audrey Meier,Lynn Mello,Sung-Sil Moon,Margie Morgan,Ruth N. Moro,Janna Murray,Rekha Murthy,Shannon A. Novosad,Sara E. Oliver,Jennifer O'Shea,Massimo Pacilli,Clinton R. Paden,Mark A. Pallansch,Manisha Patel,Sajan Patel,Isabel Pedraza,Satish K. Pillai,Talia Pindyck,Ian W. Pray,Krista Queen,Nichole Quick,Heather Reese,Brian Rha,Heather J. Rhodes,Susan Robinson,Philip Robinson,Melissa A Rolfes,Janell Routh,Rachel Rubin,Sarah L. Rudman,Senthilkumar K. Sakthivel,Sarah Scott,Christopher Shepherd,Varun Shetty,Ethan A. Smith,Shanon Smith,Bryan Stierman,William V. Stoecker,Rebecca Sunenshine,Regina Sy-Santos,Azaibi Tamin,Ying Tao,Dawn Terashita,Natalie J. Thornburg,Suxiang Tong,Elizabeth Traub,Ahmet Tural,Anna Uehara,Timothy M. Uyeki,Grace M Vahey,Jennifer R. Verani,Elsa Villarino,Megan J. Wallace,Lijuan Wang,John T. Watson,Matthew Westercamp,Brett Whitaker,Sarah Wilkerson,Rebecca C. Woodruff,Jonathan M. Wortham,Tiffany Wu,Amy Xie,Anna R Yousaf,Matthew Zahn,Jing Zhang +177 more
TL;DR: In 12 patients with mild to moderately severe illness, SARS-CoV-2 RNA and viable virus were detected early, and prolonged RNA detection suggests the window for diagnosis is long.
Journal ArticleDOI
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection
Robert Belknap,David P. Holland,Pei Jean Feng,Joan Pau Millet,Joan A. Caylà,Neil A. Martinson,Alicia Wright,Michael P. Chen,Ruth N. Moro,Nigel A. Scott,Bert Arevalo,José M. Miró,Margarita E. Villarino,Marc H Weiner,Andrey S. Borisov +14 more
TL;DR: The results support using self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection in the United States, and such treatment could be considered in similar settings when direct observation is not feasible.
Journal ArticleDOI
Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium
Susan E. Dorman,Stefan V. Goldberg,Jason E. Stout,Grace Muzanyi,John L. Johnson,Marc H Weiner,Lorna Bozeman,Charles M. Heilig,Pei Jean Feng,Ruth N. Moro,Masahiro Narita,Payam Nahid,Susan M. Ray,Edward Bates,Betial Haile,Eric L. Nuermberger,Andrew Vernon,Neil W. Schluger +17 more
TL;DR: The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase.
Journal ArticleDOI
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Susan E. Dorman,Radojka M. Savic,Stefan V. Goldberg,Jason E. Stout,Neil W. Schluger,Grace Muzanyi,John L. Johnson,Payam Nahid,Emily J. Hecker,Charles M. Heilig,Lorna Bozeman,Pei Jean I Feng,Ruth N. Moro,William R. MacKenzie,Kelly E. Dooley,Eric L. Nuermberger,Andrew Vernon,Marc H Weiner +17 more
TL;DR: Daily rifapentine was well-tolerated and safe and high rifAPentine exposures were associated with high levels of sputum sterilization at completion of intensive phase.